Pharmacodynamics of non-replicating viruses, bacteriocins and lysins

Proceedings of the Royal Society B: Biological Sciences

Volumn 273, Issue 1602, 2006, Pages 2703-2712

  Bull, James J ^a   Regoes, Roland R ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

Bacteriocins; Lysins; Mathematical model; Non lytic phage; Phage therapy; Pharmacodynamics

Indexed keywords

BACTERIOCIN;

ANTIBIOTICS; ANTIBODY; CANCER; CHEMOTHERAPY; DISEASE TREATMENT; NUMERICAL MODEL; TOXIN; VIRUS;

ADSORPTION; ARTICLE; BACTERIAL SURVIVAL; BACTERIOPHAGE; CANCER THERAPY; CELL LOSS; INFECTION CONTROL; MATHEMATICAL MODEL; PRIORITY JOURNAL; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS);

EID: 33750547156     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.2006.3640     Document Type: Article

References (49)

1. Abedon, S. T., Herschler, T. D. & Stopar, D. 2001 Bacteriophage latent-period evolution as a response to resource availability. Appl. Environ. Microbiol. 61, 4233-4241. (doi:10.1128/AEM.67.9.4233-4241.2001)
2. Adams, M. 1959 Bacteriophages. New York, NY: Interscience Publishers.
3. Bonapace, C. R., Friedrich, L. V., Bosso, J. A. & White, R. L. 2002 Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob. Agents Chemother. 46, 3574-3579. (doi:10.1128/AAC.46.11.3574-3579.2002)
4. Bouvier d'Yvoire, M. J. Y. & Maire, P. H. 1996 Dosage regimens of antibacterials. Clin. Drug Invest. 11, 229-239.
5. Boylan, C. J., Campanale, K., Iversen, P. W., Phillips, D. L., Zeckel, M. L. & Parr Jr, T. R. 2003 Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47, 1700-1706. (doi:10.1128/AAC.47. 5.1700-1706.2003)
6. Bull, J. J., Levin, B. R., DeRouin, T., Walker, N. & Bloch, C. A. 2002 Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2, 35. (doi:10.1186/1471-2180-2-35)
7. Corvaisier, S., Maire, P. H., Bouvier d'Yvoire, M. Y., Barbaut, X., Bleyzac, N. & Jelliffe, R. W. 1998 Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob. Agents Chemother. 42, 1731-1737.
8. Dalla Costa, T., Nolting, A., Rand, K. & Derendorf, H. 1997 Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int. J. Clin. Pharmacol. Ther. 35, 426-433.
9. Delacher, S., Derendorf, H., Hollenstein, U., Brunner, M., Joukhadar, C., Hofmann, S., Georgopoulos, A., Eichler, H. G. & Muller, M. 2000 A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J. Antimicrob. Chemother. 46, 733-739. (doi:10.1093/jac/46.5.733)
10. Fischetti, V. A. 2003 Novel method to control pathogenic bacteria on human mucous membranes. Ann. NY Acad. Sci. 987, 207-214.
11. Fisher, K. J., Choi, H., Burda, J., Chen, S. J. & Wilson, J. M. 1996 Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22. (doi:10.1006/viro.1996.0088)
12. Ganly, I. et al. 2000 A phase i study of onyx-015, an elb attenuated adenovirus, administered intratumprally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806.
13. Garrett, E. R. 1971 Drug action and assay by microbial kinetics. In Progress in drug research, vol. 15 (ed. E. Jucker), pp. 271-352. Basel, MA: Birkhauser Verlag.
14. Hadas, H., Einav, M., Fishov, I. & Zaritsky, A. 1997 Bacteriophage t4 development depends on the physiology of its host Escherichia coli. Microbiology 143, 179-185.
15. Hancock, R. W. & Braun, V. 1976 Nature of the energy requirement for the irreversible adsorption of bacteriophages t1 and phi80 to Escherichia coli. J. Bacteriol. 125, 409-415.
16. Hedges, A. J. 1966 An examination of single-hit and multi-hit hypotheses in relation to the possible kinetics of colicin adsorption. J. Theor. Biol. 11, 383-410. (doi:10.1016/0022-5193(66)90100-7)
17. Heise, C. & Kirn, D. H. 2000 Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105, 847-851.
18. Heise, C., Ganly, I., Kim, Y. T., Sampson-Johannes, A., Brown, R. & Kirn, D. 2000 Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene. Ther. 7, 1925-1929. (doi:10.1038/sj.gt. 3301319)
19. Hyatt, J. M., Nix, D. E., Stratton, C. W. & Schentag, J. J. 1995 In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39, 1711-1716.
20. Jacob, F., Siminovitch, L. & Wollman, E. 1952 Biosynthesis of a colicin and its mode of action. Ann. Inst. Pasteur (Paris) 83, 295-315.
21. Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H. & Craig, W. A. 1989 Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159, 281-292.
22. Levin, B. R., Stewart, F. M. & Chao, L. 1977 Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am. Nat. 111, 3-24. (doi: 10.1086/283134)
23. Louie, A., Kaw, P., Liu, W., Jumbe, N., Miller, M. H. & Drusano, G. L. 2001 Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45, 845-851. (doi:10.1128/AAC.45.3.845-851.2001)
24. Matsuda, T., Freeman, T. A., Hubert, D. W., Duff, M., Fuortes, M., Stapleton, P. P. & Daly, J. M. 2005 Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137, 639-646. (doi:10.1016/j.surg.2005.02. 012)
25. Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S. & Adhya, S. 1996 Long-circulating bacteriophage as antibacterial agents. Proc. Natl Acad. Sci. USA 93, 3188-3192. (doi:10.1073/pnas.93.8.3188)
26. Mossie, K. G., Jones, D. T., Robb, F. T. & Woods, D. R. 1979 Characterization and mode of action of a bacteriocin produced by a Bacteroides fragilis strain. Antimicrob. Agents Chemother. 16, 724-730.
27. Mouton, J. W., Vinks, A. A. & Punt, N. C. 1997 Pharmacokinetic- pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41, 733-738.
28. Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H. & Drusano, G. L. 2002 Standardization of pharmacokinetic/pharmacodynamic (pk/pd) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19, 355-358. (doi:10.1016/80924-8579(02)00031-6)
29. Mueller, M., de La Pena, A. & Derendorf, H. 2004 Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus mic. Antimicrob. Agents Chemother. 48, 369-377. (doi:10.1128/AAC.48.2. 369-377.2004)
30. Nemunaitis, J. et al. 2001 Phase ii trial of intratumoral administration of onyx-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298.
31. Nix, D. E., Wilton, J. H., Hyatt, J., Thomas, J., Strenkoski-Nix, L. C., Forrest, A. & Schentag, J. J. 1997 Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob. Agents Chemother. 41, 1108-1114.
32. Nolting, A. & Derendorf, H. 1995 Pharmacokinetic/pharmacodynamic modeling of antibiotics. In Pharmacokinetic/pharmacodynamic correlation (ed. H. Derendorf & G. Hochhaus), pp. 363-388. Boca Raton, FL: CRC Press.
33. Nolting, A., Dalla Costa, T., Rand, K. H. & Derendorf, H. 1996 Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm. Res. 13, 91-96. (doi:10.1023/A:1016085402278)
34. Payne, R. J. & Jansen, V. A. 2001 Understanding bacteriophage therapy as a density-dependent kinetic process. J. Theor. Biol. 208, 37-48. (doi:10.1006/jtbi.2000.2198)
35. Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F. & Levin, B. R. 2004 Pharmacodynamic functions: a multi-parameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48, 3670-3676. (doi:10.1128/AAC.48.10.3670-3676.2004)
36. Reynolds, B. L. & Reeves, P. R. 1969 Kinetics of adsorption of colicin ca42-e2 and reversal of its bactericidal activity. J. Bacteriol. 100, 301-309.
37. Riley, T. V. & Mee, B. J. 1985 A comparative study of three bacteriocins of Bacteroides fragilis. Microbios 43, 115-133.
38. Shannon, R. & Hedges, A. J. 1967 Kinetics of lethal adsorption of colicin e-2 by Escherichia coli. J. Bacteriol. 93, 1353-1359.
39. Smith, H. W. & Huggins, M. B. 1982 Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128, 307-318.
40. Staneva, M., Markova, B., Atanasova, I. & Terziivanov, D. 1994 Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob. Agents Chemother. 38, 981-985.
41. Tagg, J. R., Dajani, A. S. & Wannamaker, L. W. 1976 Bacteriocins of gram-positive bacteria. Bacteriol. Rev. 40, 722-756.
42. Timmis, K. & Hedges, A. J. 1972 The killing of sensitive cells by colicin d. Biochim. Biophys. Acta 262, 200-207.
43. Vinks, A. A. 2002 The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int. J. Antimicrob. Agents 19, 313-322. (doi:10.1016/S0924-8579(02)00023-7)
44. Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G. & Norris, J. S. 2003 Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47, 1301-1307. (doi:10.1128/AAC.47.4.1301-1307.2003)
45. Wodarz, D. 2001 Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61, 3501-3507.
46. Wodarz, D. 2003 Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum. Gene Ther. 14, 153-159. (doi:10.1089/104303403321070847)
47. Yano, Y., Oguma, T., Nagata, H. & Sasaki, S. 1998 Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J. Pharm. Sci. 87, 1177-1183. (doi:10.1021/js9801337)
48. Zhi, J., Nightingale, C. H. & Quintiliani, R. 1986 A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J. Pharm. Sci. 75, 1063-1067.
49. Zhi, J. G., Nightingale, C. H. & Quintiliani, R. 1988 Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J. Pharmacokinet. Biopharm. 16, 355-375. (doi:10.1007/BF01062551)